Introduction
Peripheral blood stem-cell transplantation (PBSCT) has become a curative therapy for many haematologic malignancies. However, it is often accompanied by infectious complications, which remain among the most significant causes of morbidity and mortality among high-risk patients.
Approximately two-thirds of the nosocomial infections (NI) found in patients undergoing PBSCT are blood stream infections (BSI) or pneumonia, and over 70% of NI occur during the phase of neutropenia. 1, 2 This is why the ONKO-KISS study, as part of the surveillance programme of the German National Reference Centre for Surveillance of Nosocomial Infections (KISSGerman Hospital Infection Surveillance System), focuses on these two types of infections during neutropenia, with the aim of decreasing infection rates. 3 Infection is a time-dependant outcome, observation of which may be precluded by prior death or the end of neutropenia. We therefore used statistical methods of survival analysis, for example Klein et al. 4, 5 We used the Fine-Gray regression model for the cumulative incidences of the competing events 'infection', 'death' and 'end of neutropenia' to analyse risk factors for BSI and pneumonia. 6 The cumulative incidence displays the proportion of patients experiencing a specific event, as time progresses.
Methods

Patients and surveillance
Participation by the hospitals in the ONKO-KISS surveillance system is voluntary and individual data are handled as strictly confidential. 3 Twenty hospitals in Germany, Switzerland and Austria participated in this project up to June 2004. Of this number, 70% were university hospitals, 15% were teaching hospitals and 15% district hospitals. Fourteen of the participating hospitals perform allogeneic and autologous BMT or PBSCT, while six hospitals perform autologous transplantations only. All consecutive adult patients (X16 years) with allogeneic or autologous PBSCT were included during their first phase of neutropenia in the pre-engraftment period. Follow-up terminated with the end of neutropenia. Antibiotic prophylaxis data were available at 18 hospitals. Quinolones were administered in six of the 18 hospitals, trimethoprim/sulfamethoxazole (TMP/SMX) in two of 18, quinolones and TMP/ SMX in six of 18 and TMP/SMX and a non-absorbable antibiotic in four of 18 hospitals. Infection control practitioners reported infections in neutropenic patients using CDC definitions for laboratory-confirmed BSI and modified criteria for pneumonia in neutropenic patients. 3 All of them had received 2 days of training on the surveillance of infections. Neutropenia was defined as an absolute white blood cell count (WBC) o1 Â 10 9 /l. The neutropenic phase was declared to be over once the patient had a white blood cell count 41 Â 10 9 /l for 2 days or longer. A patient was considered to have become infected during neutropenia if symptoms became manifest on day 2 or later following the onset of neutropenia. All patients with complete remission, patients with CML in their first chronic phase and all patients immediately transplanted after initial diagnosis were designated as having early disease. All patients in second remission, second chronic phase or even more advanced states for example second or third relapse, were designated as having advanced disease. The methods employed in the ONKO-KISS project are described in greater detail elsewhere 3 (NRZ homepage, www.nrzhygiene.de, study protocol in German). Data plausibility was checked by a statistician before the actual data analysis.
Statistics
We performed a competing risks analysis with the competing events defined as infection, end of neutropenia and death. [5] [6] [7] An easy-to-interpret statistical quantity of interest in this setting is the cumulative incidence function of infection, displaying the proportion of patients experiencing an infection, as time progresses. We used the FineGray regression model for the sub-distribution hazard of a competing risk to analyse the effect of baseline risk factors on the cumulative incidence function of infection. 6, 8 This regression model allows assessment of the effect of baseline covariates on the cumulative incidence function directly. All analyses were performed using the 'cmprsk' package of the statistics software R. 9 These methods allow for censored observations, that is follow-up ended during neutropenia without occurrence of NI. However, patients for whom the type of competing event is unknown were excluded from the analysis. From the data collection process we may assume that these event types are missing at random; exclusion of such data is then a legitimate strategy. 10 The risk factors known at baseline are: sex, age, underlying disease and type of transplant. For the risk factor 'underlying disease', we distinguished additionally between early and advanced disease. For the risk factor 'type of transplant' (either autologous or allogeneic); we also distinguished between related donor and unrelated donor allogeneic (URD) transplants. Baseline risk factors were first considered in univariate analyses. These results may be illustrated by plotting the cumulative incidence function for NI within strata defined by the baseline risk factors (except for age). We then performed a multivariate analysis, including those risk factors with a univariate Pp15.7%; the benchmark of 15.7% corresponds to the Akaike criterion. 11 If at least one of the two factors 'allogeneic (related donor)' or 'allogeneic (unrelated donor)' fulfilled this criterion, we included this finer distinction; we proceeded in an analogous manner for the early and advanced stage of an underlying disease. Reported P-values are based on Wald tests. All analyses are stratified for the respective hospital.
Results
From 1/2000 through 6/2004, a total of 1699 patients were investigated.
The blood stream infection (BSI) results can be summarized as follows: 1616 patients were analysed. After excluding 83 patients as described in 'Methods', 319 (19.7% of 1616) patients acquired BSI during neutropenia. 1260 (78%) patients survived neutropenia and without prior BSI. Twenty (1.2%) patients died during neutropenia without prior BSI. A further five (1.6% of 319) patients died during neutropenia after having acquired BSI. For 17 (1.1%) patients follow-up ended during neutropenia without prior occurrence of BSI.
Pneumonia results can be summarized as follows: 1595 patients were analysed. After excluding 104 patients as described in 'Methods', 125 patients (7.8% of 1595) acquired pneumonia during neutropenia. 1431 (89.7%) patients survived neutropenia and without prior pneumonia. Eighteen (1.1%) patients died during neutropenia without prior pneumonia. Seven (5.6% of 125) patients died during neutropenia after having acquired pneumonia. For 21 (1.3%) patients follow-up ended during neutropenia without prior occurrence of pneumonia. The characteristics of the cohort study for BSI are shown in Table 1 . The characteristics of the cohort study for pneumonia are similar.
In the univariate analysis, we found that male PBSCTpatients were at a significantly higher risk of acquiring BSI than female patients. Another significant risk factor was advanced disease acute myeloid leukaemia (AML), whereas patients with advanced disease non-Hodgkin lymphoma had a lower risk for BSI during neutropenia compared with all the other diseases. With regard to pneumonia, compared with autologous PBSCT transplantation allogeneic PBSCT-transplantation showed itself to be a significant risk factor, whereas patients with early disease multiple myeloma were at reduced risk (Table 2) . Selected results are demonstrated in Figures 1 and 2 .
In the multivariate analysis risk factors for BSI remained male sex and advanced disease AML, for pneumonia unrelated donor allogeneic transplantation (Table 3) .
Discussion
In this study, we analysed the risk factors for blood stream infection and pneumonia based on the multicenter ONKO-KISS surveillance data of 1699 patients undergoing PBSCT for haematologic malignancies. Although an increasing number of patients undergo PBSCT, there is limited information about base line risk factors on infections during neutropenia. [11] [12] [13] [14] In addition, data describing the time-dependent occurrence of infection are not usually analysed, whereas we did so, which gives our results further relevance.
Marena et al. 14 found allogeneic transplantation of unrelated matched or partially matched family donors to be a significant risk factor both in the univariate as well as in the multivariate analysis. However, these patients were included in the study for the duration of their hospital stay. Unlike ONKO-KISS, surveillance was not restricted to the phase of neutropenia, and risk factors were not studied in a competing risks analysis. In our univariate analysis the type of transplantation was not a risk factor for BSI.
Interestingly, in the multivariate analysis we found a significant male gender risk factor for BSI. This is in line with the finding by Martin et al. 15 who by analysing 10 319 418 cases in the US over 22 years described a higher risk for blood stream infection in men than in women (the mean annual relative risk increased to 1.28). In a subgroup analysis of patients with cancer Danai et al. 16 found significant racial and gender disparities, that is men and non-white races were at especially increased risk for sepsis.
With regard to pneumonia our data showed male gender also to constitute a close to significant risk. This might be due to the smaller number of cases of pneumonia versus BSI (total: 125 pneumonia versus 319 BSI). A prospective data analysis of 30 288 trauma patients showed that male gender was significantly associated with an increased risk for post-injury pneumonia. 17 Differences in hormonal influence have been postulated as a possible mechanism for divergence in male and female outcomes, because sex hormones have been shown to regulate cellular immunity. 18 A gender disposition for the acquisition of nosocomial infections has been described for invasive Staphylococcus aureus infections and tuberculosis. 19, 20 Furthermore, an animal study showed a higher susceptibility to Escherichia coli septicaemia in immuno-suppressed (dexamethasone) male turkeys versus female. 21 A recent study showed gender-related urine cytokine patterns in renal transplant patients with urinary tract infection. 22 Lynch et al. 23 postulate that the regulation of IL-1 secretion is fundamentally different in women and men and suggests the possibility that IL-1 may serve different biological functions. In a study investigating the benefit of antifungal prophylaxis in neutropenic patients with AML, Rex found an increased risk in males for invasive fungal infections. 24 However, there are astonishingly few data on gender disposition with respect to infections, and this deserves further research. Advanced disease AML was identified as another risk factor for BSI. It can, for instance, be hypothesized that patients with advanced disease AML develop more chemotherapy-induced neutropenias than patients with early disease AML. Therefore, they are prone to blood stream infections resulting from mucositis, colonization or translocation in the gut. 25 URD PBSCT was revealed to be a risk factor for pneumonia in the uni-and the multivariate analysis. Patients who receive a PBSCT from an URD will in general have an aggressive underlying illness. However, we could only identify this risk factor for pneumonia, but not for BSI. An explanation could be that fungal infections often cause pneumonia but are rarely identified in blood cultures (o5%). 3 
Table 1
Characteristics of the study cohort by infection of interest 
Risk factor analysis of sepsis and pneumonia after PBSCT E Meyer et al
We studied the occurrence of infections during neutropenia with a competing risk analysis customised to this goal and found that the results of our analysis were well displayed in stratified cumulative incidence plots showing how infections occur over time. We deliberately desisted from using incidence densities, that is the number of infections divided by patient-days in neutropenia because such an analysis can be misleading due to the competing risks situation: for the individual patient it is essential whether or not an infection occurs during neutropenia. Patients with lasting neutropenia may be at greater risk of eventually developing an infection, but may contribute to a (misleadingly) reduced incidence density due to the increased time of neutropenia. Thus, our analysis showed an increased risk for pneumonia in allogeneic transplanted patients, but this result is not reflected by incidence densities, since allogeneic transplanted patients tend to be neutropenic for longer.
3 Table 2 Univariate analysis of the effect of sex and age and of the effect of autologous (only PBSCT), allogeneic (donor related) and allogeneic (unrelated donor) transplants on the cumulative incidence function for pneumonia or BSI in a Fine-Gray regression model
Infection of interest Risk factor
Subdistribution hazard ratio 95%-confidence two-sided Two-sided P-value Risk factor analysis of sepsis and pneumonia after PBSCT E Meyer et al
The study has some limitations, which must be taken into account. Firstly, patients with allogeneic PBSCT were neither differentiated according to whether they had received reduced or conventional conditioning, nor by the type of antimicrobial prophylaxis that is which antibiotic was given, nor by the use of growth factors nor by HLA matching. These are known to influence both the duration of neutropenia and infectious episodes. 26 Secondly, the ONKO-KISS study was prospectively planned to investigate the occurrence of BSI and pneumonia during neutropenia. Data collection including the application of CDC definitions for infections was done by Risk factor analysis of sepsis and pneumonia after PBSCT E Meyer et al centrally trained medical staff, completeness of data was checked centrally and a feedback form sent to the participants for rechecking. Furthermore, data plausibility was checked by a statistician before the actual data analysis. However, a validation study has not been performed yet. Therefore, although there was close interaction with the study centre the accuracy of data collection was not audited.
Thirdly, selection bias cannot be excluded because participation in ONKO-KISS is voluntary.
We have provided a multi-centre risk factor analysis for pneumonia and BSI in HSCT patients. Sex differences in the risk for BSI warrants further study. The increased risk of males and patients with advanced AML for BSI, and the increased risk for pneumonia in unrelated donor allogeneic HSCT patients should be targeted for prevention of infections in these higher risk groups.
